{"preliminary_commentary":{"by_channel":{"x_thread":6,"youtube":4,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05014139\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["intravesical enfortumab vedotin"]],"indication":"non-muscle invasive bladder cancer","name":"EV-104","nct_id":"NCT05014139","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ev-104-nct05014139. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.","label":"Enfortumab vedotin: Dose escalation cohort","type":"EXPERIMENTAL"},{"description":"During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.","label":"Enfortumab vedotin: Dose expansion cohort","type":"EXPERIMENTAL"}],"collaborators":["Seagen, a wholly owned subsidiary of Pfizer"],"completion_date":{"date":"2025-09-22","type":"ACTUAL"},"conditions":["Urinary Bladder Neoplasms","Carcinoma in Situ","Carcinoma Transitional Cell","Non-muscle Invasive Bladder Cancer","NMIBC"],"enrollment":{"count":37,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Enfortumab vedotin","otherNames":["PADCEV, ASG-22CE, ASG-22ME"],"type":"DRUG"}],"last_update":"2026-09-14","lead_sponsor":"Astellas Pharma Global Development, Inc.","official_title":"A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2025-09-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Incidence of adverse events (AEs)","timeFrame":"Approximately 1 year"},{"measure":"Incidence of laboratory abnormalities","timeFrame":"Approximately 1 year"},{"measure":"Incidence of dose limiting toxicities (DLTs)","timeFrame":"Approximately 7 weeks"}],"references":[],"start_date":{"date":"2021-12-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)","url":"https://clinicaltrials.gov/study/NCT05014139"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ev-104-nct05014139"}